Lexaria Bioscience Corp. (LEXX) has released an update.
Lexaria Bioscience Corp. has commenced its second pilot study to evaluate three different semaglutide formulations aimed at improving the drug’s absorption and reducing side effects. This groundbreaking study will include an in-mouth dissolvable tablet, potentially pioneering a new delivery method for GLP-1 drugs. The study’s outcomes could have significant implications for the effectiveness and patient experience of semaglutide, a medication used in the management of type 2 diabetes.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
